Abstract
We examined the expression of basic fibroblast growth factor (FGF) and FGF receptor by immunohistochemistry in 32 human pancreatic ductal adenocarcinomas. Mild to marked basic FGF immunoreactivity was noted in 19 (59.4%) of the 32 tumours examined, and 30 (93.3%) of the tumours exhibited a cytoplasmic staining pattern against FGF receptor. The tumours were divided into two groups according to the proportion of positively stained tumour cells: a low expression group (positive cells < 25%) and a high expression group (positive cells > or = 25%). No statistically significant difference in tumour size, differentiation, metastases or stage was found between the low and high basic FGF expression groups. However, a significant correlation was found between FGF receptor expression level and the presence of retroperitoneal invasion, lymph node metastasis, and tumour stage. In addition, low FGF receptor expression was significantly associated with a longer post-operative survival as compared with high FGF receptor expression, whereas there was no significant difference in post-operative survival between the low and high basic FGF expression groups. Increased expression of FGF receptor is correlated with the extent of malignancy and post-operative survival in human pancreatic ductal adenocarcinomas. Thus, overexpression of FGF receptor may prove to be a more useful prognostic marker than basic FGF expression level in pancreatic cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohta, T., Yamamoto, M., Numata, M. et al. Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer 72, 824–831 (1995). https://doi.org/10.1038/bjc.1995.420
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.420
This article is cited by
-
Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
British Journal of Cancer (2014)
-
Ultrastructural immunolocalization of basic fibroblast growth factor in endothelial cells: morphologic evidence for unconventional secretion of a novel protein
Journal of Molecular Histology (2011)
-
Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance
Journal of Translational Medicine (2008)
-
BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion
Molecular Cancer (2007)
-
Anti-angiogenic strategies in gastrointestinal malignancies
Current Treatment Options in Oncology (2005)